<DOC>
	<DOCNO>NCT00880360</DOCNO>
	<brief_summary>This study test whether denileukin diftitox deplete regulatory T cell , boost tumor-specific immunity treat epithelial ovarian cancer patient fail , ineligible front line therapy .</brief_summary>
	<brief_title>A Trial Intravenous Denileukin Diftitox Stage III IV Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Able provide inform consent Not Immune modulate drug Life expectancy le 6 month Unable tolerate phlebotomy Germ cell stromal cell cancer ovary Active autoimmune disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Epithelial Ovarian Cancer</keyword>
	<keyword>FIGO ( International Federation Gynecology Obstetrics ) Stage III Stage IV</keyword>
	<keyword>Extraovarian Peritoneal Cancer</keyword>
	<keyword>Fallopian Tube Carcinoma Failing</keyword>
</DOC>